Results from the phase 3 monarchE trial on the addition of abemaciclib to endocrine therapy in patients with early breast cancer were presented at the 17th St. Gillen International Breast Cancer Conference.
A team of researchers sought to assess outcomes related to hypofractionated whole breast radiation following breast-conserving surgery in women aged younger than 50 years.
A team of investigators conducted a retrospective, population-based, matched-cohort study to assess outcomes in young women who were diagnosed with early-stage breast cancer.
A team of investigators sought to determine the significance of the immunologic aspects of the antitumor response and reported their findings at the 17th St. Gillen International Breast Cancer Conference 2021.
A team of investigators who conducted a meta-analysis to evaluate the safety and efficacy of tyrosine kinase inhibitors in patients with HER-2 positive breast cancer with brain metastases presented their findings at the 17th St. Gallen International Breast Cancer Conference.
A team of investigators assessed the efficacy of trastuzumab in early-stage breast cancer and presented their research at the 17th St. Gallen International Breast Cancer Conference 2021.
A team of investigators sought to identify the most accurate preoperative breast imaging technique for determining tumor size in individuals with early breast cancer.
A team of investigators conducted a meta-analysis to evaluate the efficacy and safety of dual HER2 blockade with a pertuzumab-based regimen in patients previously exposed to anti-HER2 treatment.
A team of investigators sought to evaluate safety, tolerability, and antitumor activity neoadjuvant niraparib for patients with localized breast cancer.
A team of investigators conducted a retrospective analysis to evaluate outcomes of patients with early breast cancer who were undergoing neoadjuvant chemotherapy.
Investigators surveyed patients in the international INSPIRE registry to assess the impact of adjuvant endocrine therapy on health-related quality of life in women undergoing nipple-sparing mastectomy for breast cancer.
Subcutaneous trastuzumab has the potential to reduce the number of regular clinic visits and the amount of time a patient spends in the hospital or clinic.
The LAVENDER study evaluated the safety and tolerability of ABP 980, a biosimilar approved for patients with metastatic breast cancer, early breast cancer, adjuvant breast cancer, and metastatic gastric cancer.
